Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neuronetics Inc (STIM)
NASDAQ:STIM
STIM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.52 - $5.07
Previous CloseN/A
Volume92.55K
Average Volume (3M)687.57K
Market Cap
$78.25M
Enterprise Value$50.25M
Total Cash (Recent Filing)$17.04M
Total Debt (Recent Filing)$15.65M
Price to Earnings (P/E)―
Beta2.26
Next Earnings
Mar 11, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding32,069,267
10 Day Avg. Volume1,625,886
30 Day Avg. Volume687,573
Standard Deviation0.35
R-Squared0.10
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.02
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.97
Enterprise Value/Ebitda-1.87
Forecast
1Y Price Target
$3.00Price Target Upside-0.33% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Company GrowthThe recent adolescent indication expands its total addressable market by approximately 35%.
Financial PerformanceNeuronetics announced preliminary Q4/24 results, with revenue of $22.1M ahead of $19.2M estimate and consensus of $19.0M.
Merger BenefitsThe merger with Greenbrook TMS is expected to bring pro-forma combined revenue of $145 million in 2023, growing in the mid-teens in 2025 and 2026, along with $15 million of annualized cost savings.
Bears Say
Corporate StrategyA corporate reduction in force, including the commercial organization, was undertaken in advance of the merger, contributing to a lower outlook.
Financial PerformanceThe company's third quarter reflected a top-line miss, and the full-year 2024 guidance was reduced at the midpoint, indicating ongoing challenges.
Revenue And SalesSTIM missed estimates with Q3/24 revenue of $18.5M, below both the analyst's estimate and consensus, driven by a miss in treatment session revenue.
---
Ownership Overview
10.04% Insiders
5.77% Mutual Funds
0.47% Other Institutional Investors
79.46% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
STIM FAQ
What was Neuronetics Inc’s price range in the past 12 months?
Neuronetics Inc lowest stock price was $0.52 and its highest was $5.07 in the past 12 months.
What is Neuronetics Inc’s market cap?
Neuronetics Inc’s market cap is $78.25M.
When is Neuronetics Inc’s upcoming earnings report date?
Neuronetics Inc’s upcoming earnings report date is Mar 11, 2025 which is in 40 days.
How were Neuronetics Inc’s earnings last quarter?
Neuronetics Inc released its earnings results on Nov 12, 2024. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.229 by -$0.211.
Is Neuronetics Inc overvalued?
According to Wall Street analysts Neuronetics Inc’s price is currently Overvalued.
Does Neuronetics Inc pay dividends?
Neuronetics Inc does not currently pay dividends.
What is Neuronetics Inc’s EPS estimate?
Neuronetics Inc’s EPS estimate is -0.24.
How many shares outstanding does Neuronetics Inc have?
Neuronetics Inc has 32,069,267 shares outstanding.
What happened to Neuronetics Inc’s price movement after its last earnings report?
Neuronetics Inc reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.229. Following the earnings report the stock price went down -37.273%.
Which hedge fund is a major shareholder of Neuronetics Inc?
Currently, no hedge funds are holding shares in STIM
---
Neuronetics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (-0.33% Downside)
$3.00 (-0.33% Downside)
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.27%
12-Months-Change
Fundamentals
Return on Equity
-153.94%
Trailing 12-Months
Asset Growth
-20.29%
Trailing 12-Months
Company Description
Neuronetics Inc
Neuronetics, Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.
---
STIM Company Deck
---
STIM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment. While the company reported revenue growth and improved gross margins, challenges such as increased net loss and reduced revenue guidance indicate underlying difficulties. The Greenbrook acquisition and operational efficiencies are promising, but immediate financial pressures remain.Read More>---
STIM Stock 12 Month Forecast
Average Price Target
$3.00
▼(-0.33% Downside)
Technical Analysis
Best Analysts Covering STIM
1 Year
1 Year Success Rate
6/19 ratings generated profit
1 Year Average Return
+1.22%
reiterated a buy rating 17 days ago
Copying William Plovanic's trades and holding each position for 1 Year would result in 31.58% of your transactions generating a profit, with an average return of +1.22% per trade.
---